Related Experiment Videos
Identification and management of heterozygous familial hypercholesterolemia: summary and recommendations from an
D E Bild1, R R Williams, H B Brewer
1Clinical and Genetic Epidemiology Branch, Bethesda, Maryland 20892.
Insights
Heterozygous familial hypercholesterolemia (hFH) is a common genetic disorder causing high LDL cholesterol and increased heart disease risk. Early detection and aggressive cholesterol management are crucial but often lacking, highlighting a need for better identification and treatment strategies.
Area of Science:
- Cardiovascular Genetics
- Metabolic Disorders
- Public Health
Background:
- Heterozygous familial hypercholesterolemia (hFH) affects ~1 in 500 individuals in the US, causing lifelong high LDL cholesterol.
- hFH significantly elevates the risk of premature coronary artery disease (CAD) mortality.
- Despite effective treatments, many hFH cases remain undiagnosed and undertreated.
Framework:
- Workshop convened by the National Heart, Lung, and Blood Institute (NHLBI) in July 1992.
- Focused on assessing current knowledge of hFH diagnosis and management.
- Aimed to provide effective identification and management recommendations.
Implementation:
- Emphasized evidence-based recommendations for hFH identification.
- Highlighted the importance of aggressive LDL cholesterol control.
- Discussed strategies for early detection and intervention.
Implications:
- Underscores the need for improved screening and diagnosis of hFH.
- Stresses the critical role of early and aggressive LDL cholesterol management in preventing cardiovascular events.
- Identified research gaps and intervention opportunities for hFH.
Abstract:
Heterozygous familial hypercholesterolemia (hFH) is one of the most common monogenic disorders with serious health consequences, affecting approximately 1 in 500 persons in the United States. Persons with hFH generally manifest elevations of low density lipoprotein (LDL) cholesterol throughout their lives and have a markedly increased risk of death from coronary artery disease. The hypercholesterolemia of hFH is responsive to medication and diet, and, if detected early, aggressive LDL cholesterol control may prevent or substantially delay cardiovascular disease. However, evidence suggests that many persons with hFH are undetected and inadequately treated. On July 20-21, 1992, the National Heart, Lung, and Blood Institute sponsored a workshop to assess the current understanding of the diagnosis and management of hFH, to emphasize recommendations for identification and management that are known to be effective, and to identify opportunities and needs for intervention and research.